Accessibility Menu
Diaceutics Plc logo

Diaceutics Plc(LSE) DXRX

Market Cap£120.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+50%
5 Year+23%
1 Year-0%
1 Month+3%
£1.37
-4.20%
-0.06Today
Diaceutics Plc last closing stock price
MetricPriceDate
Last closeGBX 137.002026-08-20
Diaceutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.19%GBX 144.502026-08-13
1 month+3.4%GBX 132.502026-07-21
3 month-17.72%GBX 166.502026-05-22
Year to date+7.03%GBX 128.002025-12-31
1 year-0.36%GBX 137.502025-08-20
3 year+33.66%GBX 102.502023-08-21
5 year+23.42%GBX 111.002021-08-20
Since inception+49.74%GBX 0.962019-03-21

Diaceutics Plc Financials at a Glance

Market Cap

£120.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£70.60M

Net Income (TTM)

-£1.61M

EPS (TTM)

£0.00

P/E Ratio

1300.00

Dividend

£0.00

Beta (Volatility)

-0.07 (Low)

Price

£1.37

Volume

37,469

Open

£1.41

Previous Close

£1.37

Daily Range

£1.37 - £1.41

52-Week Range

£1.25 - £1.80

Estimated Earnings Date

Sep 29, 2026

DXRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Diaceutics Plc

Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is focused on accelerating the commercialization of diagnostic solutions. The company provides global pharmaceutical firms with comprehensive data, advanced analytics, and implementation support through its innovative DXRX platform.

Products and Services
  • DXRX data solutions for extensive diagnostic testing data access
  • DXRX Patient Journey for longitudinal analyses of patient biomarker testing
  • DXRX Lab Benchmarking for competitive analysis among laboratories
Growth Outlook
  • Recent quarterly revenue increased to £23.87 million, up from £14.56 million
  • TTM gross profit margin stands at 73.8%, indicating strong operational efficiency
  • Cash and cash equivalents reached £7.34 million, supporting future growth initiatives
Financial Highlights
  • Net income for Q4 2025 was £2.50 million, a significant improvement
  • Operating income ratio improved to 13.1% in Q4 2025
  • Current ratio of 3.43 indicates strong liquidity position
Diaceutics PLC operates in the Medical - Diagnostics & Research industry, leveraging its proprietary DXRX platform to enhance the precision medicine landscape. The platform connects laboratories, pharmaceutical companies, and diagnostic firms, facilitating collaboration and innovation in diagnostics. The recent financial performance reflects a positive trajectory, with notable increases in revenue and net income, suggesting effective management and operational strategies. The company's focus on data-driven solutions positions it well for future growth in the evolving healthcare market.
AI Generated • Aug 1, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

205

CEO

Ryan Gerard Keeling

Website

diaceutics.com

Headquarters

Belfast, AT BT9 6GW, GB

DXRX Financials

Key Financial Metrics (TTM)

Gross Margin

73.80%

Operating Margin

-0.55%

Net Income Margin

0.25%

Return on Equity

0.25%

Return on Capital

0.64%

Return on Assets

0.19%

Earnings Yield

0.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£120.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

84.54M

Volume

37.47K

Avg. Volume

265.20K

Financials (TTM)

Gross Profit

£54.52M

Operating Income

-£2.68M

EBITDA

£7.98M

Operating Cash Flow

£2.30M

Capital Expenditure

-£171.00K

Free Cash Flow

£2.13M

Cash & ST Invst.

£7.34M

Total Debt

£1.15M

Diaceutics Plc Performance Analysis

Diaceutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 19,504,00039.9%
20232023-12-31GBP 23,699,00021.5%
20242024-12-31GBP 32,158,00035.7%
20252025-12-31GBP 38,437,00019.5%
Diaceutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-10.6%
Q42024-12-3161.0%
Q22025-06-30-26.6%
Q42025-12-3163.9%
Diaceutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP 0.0127.3%
20232023-12-31GBP -0.02N/A
20242024-12-31GBP -0.02-2.4%
20252025-12-31GBP 0.00N/A
Diaceutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-887.1%
Q42024-12-31134.0%
Q22025-06-30-373.1%
Q42025-12-31203.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£23.87M

+73.3%

Gross Profit

£16.28M

+47.9%

Gross Margin

68.20%

N/A

Market Cap

£120.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£589.74K

N/A

Employees

205

N/A

Net Income

£2.50M

+1057.1%

EBITDA

£6.25M

+167.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£7.34M

-55.9%

Total Debt

£1.15M

-4.4%

Accounts Receivable

£20.97M

+107.1%

Inventory

£0.00

N/A

Long Term Debt

£882.00K

-16.7%

Short Term Debt

£270.00K

-7.5%

Return on Assets

0.19%

N/A

Return on Invested Capital

-0.51%

N/A

Free Cash Flow

£680.00K

+23.9%

Operating Cash Flow

£696.00K

+13.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EKF.LEKF Diagnostics Holdings plc
£0.25-0.40%
SCLP.LScancell Holdings plc
£0.10-1.04%
BVXP.LBioventix PLC
£18.00+7.46%
VLG.LVenture Life Group plc
£0.66+3.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About DXRX

What is the current price of Diaceutics Plc?

Diaceutics Plc is trading at £1.37 per share.

What is the 52-week range for Diaceutics Plc?

Over the past 52 weeks, Diaceutics Plc has traded between £1.25 and £1.80.

How much debt does Diaceutics Plc have?

As of the most recent reporting period, Diaceutics Plc reported total debt of £1.15M.

How much cash does Diaceutics Plc have on hand?

Diaceutics Plc reported £7.34M in cash and cash equivalents in its most recent financial results.

What is Diaceutics Plc’s dividend yield?

Diaceutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services